{"name":"Melinta Therapeutics, Inc.","slug":"melinta-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Orbactiv","genericName":"Orbactiv","slug":"orbactiv","indication":"Bacterial infection of skin","status":"marketed"},{"name":"Single-Dose IV Oritavancin Diphosphate","genericName":"Single-Dose IV Oritavancin Diphosphate","slug":"single-dose-iv-oritavancin-diphosphate","indication":"Acute bacterial skin and skin structure infections (ABSSSI)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Kimyrsa","genericName":"Kimyrsa","slug":"kimyrsa","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CEM-101","genericName":"CEM-101","slug":"cem-101","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"Kimyrsa","genericName":"Kimyrsa","slug":"kimyrsa","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CEM-101","genericName":"CEM-101","slug":"cem-101","phase":"phase_2","mechanism":"CEM-101 is a potent and selective inhibitor of the histone deacetylase 6 (HDAC6) enzyme.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"Orbactiv","genericName":"Orbactiv","slug":"orbactiv","phase":"marketed","mechanism":"Small molecule","indications":["Bacterial infection of skin","Staphylococcal infection of skin","Streptococcal infection of skin"],"catalyst":""},{"name":"Single-Dose IV Oritavancin Diphosphate","genericName":"Single-Dose IV Oritavancin Diphosphate","slug":"single-dose-iv-oritavancin-diphosphate","phase":"phase_3","mechanism":"Oritavancin diphosphate is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria.","indications":["Acute bacterial skin and skin structure infections (ABSSSI)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPN0VGUkIwRGhaTlVkNTVVX1V0UTRSOHFnX1NsbnFxcE93dUhhSzJCQ1ZoWkFEMGlVa2JpUnpwYnR1a2xrbGJ5MWFVbDZ6OUVXMzMyWVFWQWtObTV0Sk9LZEVrS3VLcXR6UEFWeEdGaDNIcVJOUTlGQ01vTmtNNTNMTzhpZEdEcUZPdEV0ajg4VUdyOW1GbV8tdk5za3o5XzQ?oc=5","date":"2025-12-31","type":"pipeline","source":"The Business Journals","summary":"Venatorx Pharmaceuticals 'winds down' operations with equipment auction - The Business Journals","headline":"Venatorx Pharmaceuticals 'winds down' operations with equipment auction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE45dVBmU0VGdWN2NTkxamFaQXRnOVlQX1ZGWnh1TzljdkNhTEpDUDJTS3dFT2J6Sld3dUFCVXZWTmhTRlh1czQ1V0pnSWhxSWpnbDBMd0VaYnd0eVdQWDNybjlQOFYxLWd6VmxRSXNjTlgyTU0?oc=5","date":"2025-09-03","type":"pipeline","source":"NJBIZ","summary":"CorMedix completes $300M acquisition of Melinta Therapeutics - NJBIZ","headline":"CorMedix completes $300M acquisition of Melinta Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxONEd1X1JjYkZYYW9mWmxjNV8xUnBPSFVxSzJlUmRFNWlpQ0R0TlVPdG5JdmF1eGN5bF85UTNkZFo2eWhsaWZOSnppdksyRnd6dE9sQ3EyeFFGM3Y2Ynk0VGhtVF9SNFBsZ09xVmlhNGo2VFpxcFY5Z3hyRW5FSk1SVzFyMFFaVURQWkNIRFdlMXBGa2dxZi1VZjRNenU3VThlZ0xMTHhTUWVWdw?oc=5","date":"2025-08-14","type":"deal","source":"BioXconomy","summary":"CorMedix broadens infectious disease portfolio with $300m Melinta buy - BioXconomy","headline":"CorMedix broadens infectious disease portfolio with $300m Melinta buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPVXlvRzB2b2pYWUdueDhDaTZJTVY5UWV6YmNoTnhUNmxhaXBmcDlHTkJzd0xGLTlYN0ZKQnUtekN5cjNrS1cxUnRpNFVSbkk4RlZtYktpc09hNXBnQWVndEpBelZpZ3RDaVVPanBDMFNuVlNzcmNLbklfZUZmeDJ5VzNYOTI?oc=5","date":"2025-08-08","type":"deal","source":"Pharmaceutical Technology","summary":"CorMedix signs agreement to acquire Melinta for $300m - Pharmaceutical Technology","headline":"CorMedix signs agreement to acquire Melinta for $300m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQMi1fUl9sRWd5a1AxbVFjZWJpTmd4WXdURlYzMnJtcmtpX0kzUDBWUWh0c0tOeUt6M21SQzEwdDZ1WUhCNDdhWmp2TkZGOVZ6TVBWQkZRdVZlM3JkdGtXSldiTEFXRlphakgzZlFVSEFqTUJwV3Z3VzdKNmo2eF9RUXltSDJCZ2VfWkY3WmJwUzNhS05nSUE?oc=5","date":"2025-08-07","type":"pipeline","source":"fiercepharma.com","summary":"CorMedix expands infectious disease portfolio with $300M acquisition of Melinta - fiercepharma.com","headline":"CorMedix expands infectious disease portfolio with $300M acquisition of Melinta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNWEE0SkhCVUF4SzVkM2JzUWJ2YXJneS1SckdiWm00OGYwbWJOOWtoNVBaZGJObENwTFI5NzQ2Uktvc29KNElsRjV6UG1XU1dmMnRaM1dqWTBpRFQwaDd4TFdwME12djBYZjdDUm5MMFVqbXZieF8ydThfY242czh0S19JQ0dSbVJmTVV6V21IdFpvQXYwbFVEWHZkaFo5dW5sYVZsUm1UbV9SQldiVEFPRjd2ZlAtV1VYM05felhYRF9GUUlyX01lVmt2Ylh2bFFxVHZQX2FXdlBrU2EzcTJTaFpadGJFU0VEbFRNTm9JRUl0NXBVSWRxeHNxc1hhX1JjM0tQT01RYlA2Zw?oc=5","date":"2025-08-07","type":"pipeline","source":"Business Wire","summary":"Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership - Business Wire","headline":"Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadersh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQaEozdGdFblRQRV9haGpLaWZRUnF3VFN5WWZTckEwdDl2TTRQMVV3RzFiT3lualZPcUJKZGFKc2swVmg1LWlKNlo0ZGxFd2J6cEN3Q01rNzNOLVBNdmtWVE5HOUZrTkJEQktsX29xMUFCZjNBU0FHckhRSlFaS1pBdWtCa1EyVzJySEZMWEJfZzVDa1E?oc=5","date":"2025-08-07","type":"deal","source":"roi-nj.com","summary":"CorMedix buys Melinta Therapeutics for $300M - roi-nj.com","headline":"CorMedix buys Melinta Therapeutics for $300M - roi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPdnE3TU8tRjA2Rjh4cHJFWDdaVDRrNksyaTl1NF9oaUhHNXhabjl3UmQ3UllxRFh6a1FUSVEwU2hNNVUwa0xxUUg0Z3R1aEVuaDF6bDNJVnRTSTMybUkzaXQyNk1kdmZKU1ZkWlRoUkNrdUphLTBSbzZ3OVRpN3kyVXhCcUxhZF94UkhGQ25LY2lNUnRpXzA1MldydnZ6a3ROSkhqTjYtVi1fVTdqY2oxUy1GYllORDVHUkRxZElvUC13VDJpeHdhR0Roc0VXd0l4U0lrRVFHem1pelJKXzJSTERaSTBsVVFNcUtxVjNOZnRoWDN0VXhjcEVKR1RsQmhTaEh4cjFBS2M5X1U?oc=5","date":"2025-06-12","type":"regulatory","source":"TMX Newsfile","summary":"Xediton Pharmaceuticals Inc. (\"Xediton\") Announced Today the Canadian Approval and Availability of Vabomere(r) (Meropenem-Vaborbactam) in Canada - TMX Newsfile","headline":"Xediton Pharmaceuticals Inc. (\"Xediton\") Announced Today the Canadian Approval and Availability of Vabomere(r) (Meropene","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQbVVSTGg3YWJiRzdEZGQ2cFlOSk9kR242QzFuM194SjJ0U21QS2JjQU40VkhBZlhOTGFjbDNfeVVkVVVYcVQ2cy1ZdXAxRzBYMjNOSWhLTUdkNURMVHBPTi1NODkydUlkMkl4cWdGUGhjaVlLbnpfTVdoaldFU2xQWDluSlZJSXRNRFZaTkFZQ2k3Mm9Oclhjd1lIcnlPNkdPSFhkX3pHLVFBM20yemM5UA?oc=5","date":"2024-03-13","type":"pipeline","source":"emjreviews.com","summary":"Melinta Therapeutics’s Christine Miller on being fuelled by purpose - emjreviews.com","headline":"Melinta Therapeutics’s Christine Miller on being fuelled by purpose","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQSUFoZ3dNbkp5aGNxOUczNlFzSjBWV0VURmI1cktwOXU4QVRvSWtkRXhhbkFaQ0ZiZktBMWhTeHJrY015LWRvNDN1eFdKVEQydUI0SGxjZC1jY3RjZGVwM1VremJkTGhXZ2NOOEk2RVV6dFlwb3ZRTS03Yjh5S2ZXc2dFQnRSSUdYQzk1WHdyTGV0RDJQNVhISGFfT3J0MjdpSUZyME1VMlVvUS03ZVVvWE85NmFWZjZPMURIUjBXV2luN1lJ?oc=5","date":"2023-11-11","type":"deal","source":"Contagion Live","summary":"Melinta Therapeutics Partnering with Venatorx Pharmaceuticals on Commercializing Antibiotic - Contagion Live","headline":"Melinta Therapeutics Partnering with Venatorx Pharmaceuticals on Commercializing Antibiotic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPVHo3b3VzOVNFV3dTX2FfaTN6OGZmczFwWnN0UV8zUF9ieDYwaC1iR2hlZTdLNlAxeVJ5VTJ1aHBoWGpEX0RhMUJoVG5SOWN0UGJYbXdoX1FrOUhNMjFHY19DWTdHbVlxWFBhc1RnZkMtTEZDbHhsQktSV2dncUdVbkl6TDJQX1Myc3EwOUtQdE5yMGJQQUtJ?oc=5","date":"2022-10-06","type":"pipeline","source":"Pharma Voice","summary":"Her antibiotic company failed. Now she’s helping others avoid the same fate. - Pharma Voice","headline":"Her antibiotic company failed. Now she’s helping others avoid the same fate.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPWjBBSWlYdFgwTG5CVmFYQUoteGFmZTMwR1ZmaEhMNFBfb1VmZmtJY1JweG5XdlpJQkdTU09WVkZnZWk0R1Q2TEZQdHpteVZ3ME1YaDZ4a1ZvSjE2S3lEZ3RsMkhNTEhNMkJfWmpwbUV3V3Q2bjdFZ2ZoOWJweXUybW5LQ2k4Zm0xMGRRVWYwWUdLdw?oc=5","date":"2020-06-24","type":"trial","source":"BioPharma Dive","summary":"By $4M, La Jolla outbids Melinta for struggling Tetraphase - BioPharma Dive","headline":"By $4M, La Jolla outbids Melinta for struggling Tetraphase","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}